Shionogi & Co Ltd Executive and Leadership Team

Takeshi Kasuya, the Chief Executive Officer at Shionogi & Co Ltd, directs the company's overarching strategic vision and operational execution. Kasuya guides Shionogi's commitment to addressing urgent global health needs, particularly in infectious diseases, by fostering an environment of relentless innovation. This leadership role involves aligning research and development priorities with market demands and patient outcomes, ensuring the company remains at the forefront of therapeutic advancements. Kasuya oversees the integration of internal discovery efforts with external partnerships, accelerating the delivery of novel treatments. The Chief Executive Officer's focus extends to optimizing resource allocation and driving sustainable growth across all business units. By championing a culture of scientific excellence and patient-centricity, Takeshi Kasuya ensures Shionogi & Co Ltd consistently pursues its mission to improve lives worldwide through impactful pharmaceutical solutions.

Isao Teshirogi, the Representative Director, President & Chief Executive Officer at Shionogi & Co Ltd, spearheads the company's strategic direction and global operations. Teshirogi drives Shionogi's dedication to tackling significant health challenges, with a particular emphasis on infectious diseases and unmet medical needs. This executive position involves orchestrating the company's research, development, and commercialization efforts to bring life-saving therapies to patients efficiently. Isao Teshirogi fosters critical collaborations with academic institutions, government bodies, and industry partners to accelerate scientific discovery and therapeutic innovation. The President & Chief Executive Officer ensures robust pipeline development and market access strategies, reinforcing Shionogi's position as a leader in antibiotic, HIV, and influenza treatments. By maintaining a sharp focus on urgent patient requirements and scientific advancement, Isao Teshirogi guides Shionogi & Co Ltd in its mission to enhance global health outcomes.

Akira Kato, the President and C E O at Shionogi & Co Ltd, drives the company's strategic initiatives and operational performance. Kato guides Shionogi's commitment to developing innovative treatments that address critical global health challenges, with a strong emphasis on infectious diseases. This leadership position involves overseeing the integration of research, development, and commercial activities to ensure timely delivery of novel therapies to patients. Akira Kato fosters strategic alliances with research institutions and industry partners, accelerating the advancement of Shionogi's scientific programs. The President and C E O ensures that the company's resources are effectively deployed to maximize therapeutic impact and market reach. By championing a culture of scientific rigor and patient focus, Akira Kato reinforces Shionogi & Co Ltd's dedication to improving lives through pioneering pharmaceutical solutions and addressing urgent medical needs with precision.

Tsutae Nagata, the Chief Medical Officer at Shionogi & Co Ltd, leads the company's clinical development and medical affairs strategies. Nagata directs the rigorous evaluation of novel therapies, ensuring they meet the highest standards of safety and efficacy for patients worldwide. This critical role involves overseeing all aspects of clinical trials, from early-stage research to late-stage regulatory submissions, particularly for infectious diseases like HIV, influenza, and emerging viral threats. The Chief Medical Officer collaborates closely with internal research teams and external medical experts to translate scientific findings into tangible patient benefits. Tsutae Nagata's responsibilities include shaping the medical strategy for Shionogi's pipeline, guiding the development of innovative treatments that address pressing global health concerns. By ensuring scientific integrity and patient-centricity in all medical endeavors, Tsutae Nagata significantly contributes to Shionogi & Co Ltd's mission of improving lives through advanced pharmaceutical solutions.